NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study
Publication
, Conference
Paredes, AH; Trotter, JF; Bashir, MR; Neff, GW; Abdelmalek, MF; Ortiz-Lasanta, G; Jaros, M; Baxter, BA; Ling, L; Rossi, S; DePaoli, A; Harrison, SA
Published in: HEPATOLOGY
December 1, 2018
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
December 1, 2018
Volume
68
Issue
6
Start / End Page
1460A / 1461A
Location
Washington, DC
Publisher
WILEY
Conference Name
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Paredes, A. H., Trotter, J. F., Bashir, M. R., Neff, G. W., Abdelmalek, M. F., Ortiz-Lasanta, G., … Harrison, S. A. (2018). NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study. In HEPATOLOGY (Vol. 68, pp. 1460A-1461A). Washington, DC: WILEY.
Paredes, Angelo H., James F. Trotter, Mustafa R. Bashir, Guy W. Neff, Manal F. Abdelmalek, Grisell Ortiz-Lasanta, Mark Jaros, et al. “NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study.” In HEPATOLOGY, 68:1460A-1461A. WILEY, 2018.
Paredes AH, Trotter JF, Bashir MR, Neff GW, Abdelmalek MF, Ortiz-Lasanta G, et al. NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study. In: HEPATOLOGY. WILEY; 2018. p. 1460A-1461A.
Paredes, Angelo H., et al. “NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study.” HEPATOLOGY, vol. 68, no. 6, WILEY, 2018, pp. 1460A-1461A.
Paredes AH, Trotter JF, Bashir MR, Neff GW, Abdelmalek MF, Ortiz-Lasanta G, Jaros M, Baxter BA, Ling L, Rossi S, DePaoli A, Harrison SA. NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study. HEPATOLOGY. WILEY; 2018. p. 1460A-1461A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
December 1, 2018
Volume
68
Issue
6
Start / End Page
1460A / 1461A
Location
Washington, DC
Publisher
WILEY
Conference Name
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics